Hit ID - Quality and diversity of initial hits determines chance of success; careful triage is essential.
LO - Ideally progress multiple, structurally distinct and patentable lead series and progress into late LO as early as possible – don’t wait for the “perfect” molecule, but move several differentiated compounds forward if possible.
H2L - Focus on creating novelty and FTO through scaffold-hopping, nitrogen-walk, unique building blocks, while monitoring drug-likeness parameters and ADME early; taking advantage of handles for quick parallel SAR exploration.
Late LO/PCC - Narrow down to 2-3 compounds to select for PCC candidate and backup compound(s); connect with PRD and FormDev (“Solution Engine”) scientists early.
Oncology
Immunology & Inflammation
Metabolic disorders
Enzymes
G-protein coupled receptors (GPCRs)
Nuclear hormone receptors
Ion channels
Epigenetics-related targets
TPD platform
Oligonucleotide drug platform
Peptides
Antibodies and ADCs
Gene editing
Stable cell line generation
Protein science
Biophysics and fragment-based drug discovery (FBDD)
In-vitro safety assays